Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 8/2015

01-08-2015 | Research Article

Impact of TGF-β1 -509C/T and 869T/C polymorphisms on glioma risk and patient prognosis

Authors: Joana Vieira de Castro, Céline S. Gonçalves, Sandra Costa, Paulo Linhares, Rui Vaz, Ricardo Nabiço, Júlia Amorim, Marta Viana-Pereira, Rui M. Reis, Bruno M. Costa

Published in: Tumor Biology | Issue 8/2015

Login to get access

Abstract

Transforming growth factor beta (TGF-β) plays an important role in carcinogenesis. Two polymorphisms in the TGF-β1 gene (-509C/T and 869T/C) were described to influence susceptibility to gastric and breast cancers. The 869T/C polymorphism was also associated with overall survival in breast cancer patients. In the present study, we investigated the relevance of these TGF-β1 polymorphism in glioma risk and prognosis. A case-control study that included 114 glioma patients and 138 cancer-free controls was performed. Single nucleotide polymorphisms (SNPs) were evaluated by polymerase chain reaction followed by restriction fragment length polymorphism (PCR-RFLP). Univariate and multivariate logistic regression analyses were used to calculate odds ratio (OR) and 95 % confidence intervals (95 % CI). The influence of TGF-β1 -509C/T and 869T/C polymorphisms on glioma patient survival was evaluated by a Cox regression model adjusted for patients’ age and sex and represented in Kaplan-Meier curves. Our results demonstrated that TGF-β1 gene polymorphisms -509C/T and 869T/C are not significantly associated with glioma risk. Survival analyses showed that the homozygous -509TT genotype associates with longer overall survival of glioblastoma (GBM) patients when compared with patients carrying CC + CT genotypes (OR, 2.41; 95 % CI, 1.06–5.50; p = 0.036). In addition, the homozygous 869CC genotype is associated with increased overall survival of GBM patients when compared with 869TT + TC genotypes (OR, 2.62; 95 % CI, 1.11–6.17; p = 0.027). In conclusion, this study suggests that TGF-β1 -509C/T and 869T/C polymorphisms are not significantly associated with risk for developing gliomas but may be relevant prognostic biomarkers in GBM patients.
Literature
1.
Boyle P, Levin B. World cancer report 2008. IARC Press, International Agency for Research on Cancer, 2008.
2.
Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006;2:494–503. quiz 491 p following 516.CrossRefPubMed
3.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 who classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.CrossRefPubMedPubMedCentral
4.
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–12.CrossRefPubMedPubMedCentral
5.
Butowski NA, Sneed PK, Chang SM. Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol. 2006;24:1273–80.CrossRefPubMed
6.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.CrossRefPubMed
7.
Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il’yasova D, et al. Brain tumor epidemiology: consensus from the brain tumor epidemiology consortium. Cancer. 2008;113:1953–68.CrossRefPubMedPubMedCentral
8.
Reuss D, von Deimling A. Hereditary tumor syndromes and gliomas. Recent Results Cancer Res. 2009;171:83–102.CrossRefPubMed
9.
Wrensch M, Lee M, Miike R, Newman B, Barger G, Davis R, et al. Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. Am J Epidemiol. 1997;145:581–93.CrossRefPubMed
10.
Hocking B. Occupational exposure to ionizing and non-ionizing radiation and risk of glioma. Occup Med (Lond). 2008;58:148–9. author reply 149.CrossRef
11.
Ron E, Modan B, Boice Jr JD, Alfandary E, Stovall M, Chetrit A, et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med. 1988;319:1033–9.CrossRefPubMed
12.
Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009;41:899–904.CrossRefPubMedPubMedCentral
13.
Wrensch M, Jenkins RB, Chang JS, Yeh RF, Xiao Y, Decker PA, et al. Variants in the cdkn2b and rtel1 regions are associated with high-grade glioma susceptibility. Nat Genet. 2009;41:905–8.CrossRefPubMedPubMedCentral
14.
15.
Derynck R, Zhang YE. Smad-dependent and smad-independent pathways in tgf-beta family signalling. Nature. 2003;425:577–84.CrossRefPubMed
16.
Kaminska B, Kocyk M, Kijewska M. Tgf beta signaling and its role in glioma pathogenesis. Adv Exp Med Biol. 2013;986:171–87.CrossRefPubMed
17.
Rich JN. The role of transforming growth factor-beta in primary brain tumors. Front Biosci. 2003;8:e245–60.CrossRefPubMed
18.
Penuelas S, Anido J, Prieto-Sanchez RM, Folch G, Barba I, Cuartas I, et al. Tgf-beta increases glioma-initiating cell self-renewal through the induction of lif in human glioblastoma. Cancer Cell. 2009;15:315–27.CrossRefPubMed
19.
Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, et al. A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res. 2003;63:2610–5.PubMed
20.
Cai Q, Tang Y, Zhang M, Shang Z, Li G, Tian J, et al. Tgfbeta1 leu10pro polymorphism contributes to the development of prostate cancer: evidence from a meta-analysis. Tumour Biol. 2014;35:667–73.CrossRefPubMed
21.
Chang WW, Zhang L, Su H, Yao YS. An updated meta-analysis of transforming growth factor-beta1 gene: three polymorphisms with gastric cancer. Tumour Biol. 2014;35:2837–44.CrossRefPubMed
22.
Migita K, Miyazoe S, Maeda Y, Daikoku M, Abiru S, Ueki T, et al. Cytokine gene polymorphisms in japanese patients with hepatitis b virus infection–association between tgf-beta1 polymorphisms and hepatocellular carcinoma. J Hepatol. 2005;42:505–10.CrossRefPubMed
23.
Li K, Xia F, Zhang K, Mo A, Liu L. Association of a tgf-b1-509c/t polymorphism with gastric cancer risk: a meta-analysis. Ann Hum Genet. 2013;77:1–8.CrossRefPubMed
24.
Gonzalez-Zuloeta Ladd AM, Arias-Vasquez A, Siemes C, Coebergh JW, Hofman A, Witteman J, et al. Transforming-growth factor beta1 leu10pro polymorphism and breast cancer morbidity. Eur J Cancer. 2007;43:371–4.CrossRefPubMed
25.
Shu XO, Gao YT, Cai Q, Pierce L, Cai H, Ruan ZX, et al. Genetic polymorphisms in the tgf-beta 1 gene and breast cancer survival: a report from the shanghai breast cancer study. Cancer Res. 2004;64:836–9.CrossRefPubMed
26.
Ewart-Toland A, Chan JM, Yuan J, Balmain A, Ma J. A gain of function tgfb1 polymorphism may be associated with late stage prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:759–64.PubMed
27.
Kang HG, Chae MH, Park JM, Kim EJ, Park JH, Kam S, et al. Polymorphisms in tgf-beta1 gene and the risk of lung cancer. Lung Cancer. 2006;52:1–7.CrossRefPubMed
28.
Luedecking EK, DeKosky ST, Mehdi H, Ganguli M, Kamboh MI. Analysis of genetic polymorphisms in the transforming growth factor-beta1 gene and the risk of alzheimer’s disease. Hum Genet. 2000;106:565–9.CrossRefPubMed
29.
Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet. 1999;8:93–7.CrossRefPubMed
30.
Kaklamani VG, Baddi L, Liu J, Rosman D, Phukan S, Bradley C, et al. Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Res. 2005;65:3454–61.PubMed
31.
Watanabe Y, Kinoshita A, Yamada T, Ohta T, Kishino T, Matsumoto N, et al. A catalog of 106 single-nucleotide polymorphisms (snps) and 11 other types of variations in genes for transforming growth factor-beta1 (tgf-beta1) and its signaling pathway. J Hum Genet. 2002;47:478–83.CrossRefPubMed
32.
Li X, Yue ZC, Zhang YY, Bai J, Meng XN, Geng JS, et al. Elevated serum level and gene polymorphisms of tgf-beta1 in gastric cancer. J Clin Lab Anal. 2008;22:164–71.CrossRefPubMed
33.
Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342:1350–8.CrossRefPubMed
34.
Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol. 2005;23:2078–93.CrossRefPubMed
35.
Derynck R, Akhurst RJ, Balmain A. Tgf-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001;29:117–29.CrossRefPubMed
36.
Mullenbach R, Lagoda PJ, Welter C. An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet. 1989;5:391.PubMed
37.
Wu GY, Hasenberg T, Magdeburg R, Bonninghoff R, Sturm JW, Keese M. Association between egf, tgf-beta1, vegf gene polymorphism and colorectal cancer. World J Surg. 2009;33:124–9.CrossRefPubMed
38.
Lima-Ramos V, Pacheco-Figueiredo L, Costa S, Pardal F, Silva A, Amorim J, et al. Tp53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas. Cancer Genet Cytogenet. 2008;180:14–9.CrossRefPubMed
39.
Liu Y, Scheurer ME, El-Zein R, Cao Y, Do KA, Gilbert M, et al. Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev. 2009;18:204–14.CrossRefPubMedPubMedCentral
40.
Wang LE, Bondy ML, Shen H, El-Zein R, Aldape K, Cao Y, et al. Polymorphisms of DNA repair genes and risk of glioma. Cancer Res. 2004;64:5560–3.CrossRefPubMed
41.
Wiencke JK, Aldape K, McMillan A, Wiemels J, Moghadassi M, Miike R, et al. Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in o6-methylguanine-DNA-methyltransferase. Cancer Epidemiol Biomark Prev. 2005;14:1774–83.CrossRef
42.
Elexpuru-Camiruaga J, Buxton N, Kandula V, Dias PS, Campbell D, McIntosh J, et al. Susceptibility to astrocytoma and meningioma: influence of allelism at glutathione s-transferase (gstt1 and gstm1) and cytochrome p-450 (cyp2d6) loci. Cancer Res. 1995;55:4237–9.PubMed
43.
Zhao P, Zhao L, Zou P, Lu A, Liu N, Yan W, et al. Genetic oxidative stress variants and glioma risk in a chinese population: a hospital-based case-control study. BMC Cancer. 2012;12:617.CrossRefPubMedPubMedCentral
44.
Costa BM, Ferreira P, Costa S, Canedo P, Oliveira P, Silva A, et al. Association between functional egf + 61 polymorphism and glioma risk. Clin Cancer Res. 2007;13:2621–6.CrossRefPubMed
45.
Costa BM, Viana-Pereira M, Fernandes R, Costa S, Linhares P, Vaz R, et al. Impact of egfr genetic variants on glioma risk and patient outcome. Cancer Epidemiol Biomarkers Prev. 2011;20:2610–7.CrossRefPubMed
46.
Jiang H, Lian M, Xie J, Li J, Wang M. Three single nucleotide polymorphisms of the vascular endothelial growth factor (vegf) gene and glioma risk in a chinese population. J Int Med Res. 2013;41:1484–94.CrossRefPubMed
47.
48.
Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, et al. The l10p polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk. Cancer Lett. 2003;201:181–4.CrossRefPubMed
49.
Qi P, Ruan CP, Wang H, Zhou FG, Zhao YP, Gu X, et al. 509c>t polymorphism in the tgf-beta1 gene promoter is not associated with susceptibility to and progression of colorectal cancer in chinese. Color Dis: Off J Assoc Coloproctol G B Irel. 2010;12:1153–8.CrossRef
50.
Crivello A, Giacalone A, Vaglica M, Scola L, Forte GI, Macaluso MC, et al. Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma. Ann N Y Acad Sci. 2006;1089:98–103.CrossRefPubMed
51.
Macarthur M, Sharp L, Hold GL, Little J, El-Omar EM. The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of scotland. Cancer Epidemiol Biomarkers Prev. 2005;14:1613–8.CrossRefPubMed
52.
Saltzman BS, Yamamoto JF, Decker R, Yokochi L, Theriault AG, Vogt TM, et al. Association of genetic variation in the transforming growth factor beta-1 gene with serum levels and risk of colorectal neoplasia. Cancer Res. 2008;68:1236–44.CrossRefPubMedPubMedCentral
53.
Zhang Y, Liu B, Jin M, Ni Q, Liang X, Ma X, et al. Genetic polymorphisms of transforming growth factor-beta1 and its receptors and colorectal cancer susceptibility: a population-based case-control study in china. Cancer Lett. 2009;275:102–8.CrossRefPubMed
54.
Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M, et al. Add-on anti-tgf-beta antibody to ace inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol: JASN. 2003;14:1816–24.CrossRefPubMed
Metadata
Title
Impact of TGF-β1 -509C/T and 869T/C polymorphisms on glioma risk and patient prognosis
Authors
Joana Vieira de Castro
Céline S. Gonçalves
Sandra Costa
Paulo Linhares
Rui Vaz
Ricardo Nabiço
Júlia Amorim
Marta Viana-Pereira
Rui M. Reis
Bruno M. Costa
Publication date
01-08-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 8/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3343-0

Other articles of this Issue 8/2015

Tumor Biology 8/2015 Go to the issue

Research Article

Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis

Research Article

MicroRNA-335 represents an independent prognostic marker in cervical cancer

Research Article

Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast

Research Article

Prognostic significance of the recurrence pattern and risk factors for recurrence in patients with proximal gastric cancer who underwent curative gastrectomy

Research Commentary

PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer

Research Article

Clinicopathological significance and potential drug target of O6-methylguanine-DNA methyltransferase in colorectal cancer: a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits